Shin Cheolmin, Pae Chi-Un, Kwak Kyung Phil, Jeon Sang Won, Jeong Hyun-Ghang, Kim Jong-Woo, Lee Youn Jung, Patkar Ashwin A, Han Changsu
Department of Psychiatry, Korea University College of Medicine, Seoul, Korea.
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Clin Psychopharmacol Neurosci. 2021 May 31;19(2):243-253. doi: 10.9758/cpn.2021.19.2.243.
Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual symptoms in the patients with partially remitted MDD.
We retrospectively analyzed the 8-week medical records of the patients. The enrolled patients did respond to treatment of antidepressant but were not remitted. The range of 17-item Hamilton Depression Rating Scale (HAMD) total score of the subjects were 8 to 15 points. All patients were currently taking antidepressants when they started aripiprazole. The primary endpoint was the mean change of Clinically Useful Depression Outcome Scale (CUDOS). Secondary endpoint measures were HAMD, Clinical Global Impression-severity (CGI-S) scores, Patient Health Questionnaire-15 (PHQ-15), Beck Anxiety Inventory (BAI), Perceived Deficit Questionnaire-depression (PDQ-D), Sheehan Disability Scale (SDS) and General Health Questionnaire/Quality of Life-12 (GHQ/QL-12).
A total of 134 medical records were analyzed. The changes of CUDOS, HAMD, CGI-S, BAI, PHQ-15, PDQ-D, SDS and GHQ/QL-12 from baseline to the endpoint were -7.93, -3.29, -0.80, -4.02, -2.05, -4.35, -4.77 and -2.82, respectively (all p < 0.001). At the endpoint, the newly remitted subjects rate by HAMD score criteria were approximately 46%.
Our preliminary findings have presented the effectiveness of aripiprazole augmentation for residual symptoms of partially remitted MDD patients in routine practice. This study assures subsequent well-controlled studies of the possibility of generalizing the above promising outcome in the future.
许多重度抑郁症（MDD）患者存在残留症状，无法实现症状缓解。然而，针对MDD残留症状的药物治疗选择有限。本研究旨在探讨阿立哌唑增效治疗部分缓解的MDD患者残留症状的疗效。
我们回顾性分析了患者的8周病历。纳入的患者对 antidepressant治疗有反应但未缓解。受试者17项汉密尔顿抑郁量表（HAMD）总分范围为8至15分。所有患者在开始使用阿立哌唑时均正在服用 antidepressant。主要终点是临床有用抑郁结果量表（CUDOS）的平均变化。次要终点指标包括HAMD、临床总体印象-严重程度（CGI-S）评分、患者健康问卷-15（PHQ-15）、贝克焦虑量表（BAI）、感知缺陷问卷-抑郁（PDQ-D）、希恩残疾量表（SDS）和一般健康问卷/生活质量-12（GHQ/QL-12）。
共分析了134份病历。从基线到终点，CUDOS、HAMD、CGI-S、BAI、PHQ-15、PDQ-D、SDS和GHQ/QL-12的变化分别为-7.93、-3.29、-0.80、-4.02、-2.05、-4.35、-4.77和-2.82（所有p<0.001）。在终点时，根据HAMD评分标准新达到缓解的受试者比例约为46%。
我们的初步研究结果表明，在常规实践中，阿立哌唑增效治疗部分缓解的MDD患者残留症状有效。本研究为后续在未来推广上述有前景的结果的可能性进行严格对照研究提供了依据。
